UNSPSC 51285308: Furaltadone

This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5X4V82ZN30. European Medicines Agency schedules Furaltadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07831MIG. Furaltadone generally arises in the molecular formula C13H16N4O6.

UNSPSC 51285308 Furaltadone, a Commodity code, shows minimal alignment between the code designation and actual state and local procurement activity. The code nominally identifies furaltadone, a veterinary antimicrobial pharmaceutical, yet the recent opportunities tagged under it involve naloxone (an opioid overdose reversal agent), direct-to-manufacturer prescription programs, emergency medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and over-the-counter products for state and local health systems. None of these procurements directly involve furaltadone. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The code shows little relevant recent activity and reflects a classification mismatch rather than genuine market demand under the furaltadone code itself.

The geographic spread across recent tagged opportunities includes Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative structure, though none of these procurement efforts centers on the product the code nominates. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2026), the City of Tampa's ITB for medical and first aid supplies for fire rescue (due March 13, 2026, with an estimated contract value of $700,000), the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (due April 3, 2026), and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026). Business development professionals should treat this code as dormant for furaltadone specifically and verify actual commodity codes for pharmaceutical and health-supply opportunities before pursuing state and local work in this segment.